VenterPharma
Private Company
Funding information not available
Overview
VenterPharma is a private, commercial-stage diagnostics company based in Barcelona, Spain, founded in 2015 (with roots dating to 2003). It has developed and commercialized LacTEST, a non-invasive diagnostic drug for lactose malabsorption, along with associated analysis methods (Osaxyl and Xylossay). The company is revenue-generating, with its products financed by the Spanish public health system, and maintains an R&D pipeline targeting other digestive pathologies. Its strategy centers on providing simple, effective, and cost-effective diagnostic solutions for gastroenterology.
Technology Platform
Diagnostic platform based on gaxilose (4-galactosylxylose), a synthetic sugar analog used as a probe to directly measure intestinal lactase enzyme activity. The system includes the oral diagnostic drug and two associated analysis methods (automated and in-situ) for detecting the released xylose metabolite.
Opportunities
Risk Factors
Competitive Landscape
Competes primarily with the well-established hydrogen/methane breath test for lactose intolerance, which is widely available but less specific. Also faces potential competition from genetic tests for lactase non-persistence. As a developer of a proprietary diagnostic drug, it occupies a specialized niche with fewer direct competitors compared to standard laboratory test kits.